Page 13 - சேதி லெவிஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Molecular Partners Announces Intention to Conduct a Registered Offering in the United States
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Molecular Partners AG: Molecular Partners Announces Intention to Conduct a Registered Offering in the United States
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
State Rep. Seth Lewis (R-45th) posted a photo of himself and his family celebrating St. Patrick’s Day on his Facebook page.
Lewis wrote, “Wonderful weekend of family celebrations: birthdays, pre-St. Paddy’s, BHS/Clark 2021 Conference Championship so blessed that Max could join us for all of it! Grateful and thankful for everyone and everything!”
Despite the pandemic, some are still celebrating St. Patrick’s Day with a few adjustments. Mayor Lori Lightfoot continued the longtime Chicago tradition of dyeing the Chicago River green, but didn’t announce it beforehand because she didn t want crowds to gather.
Trending
Provided by Accesswire
Mar 15, 2021 6:00 AM UTC
ACTIV-3 trial planned to investigate safety and efficacy of ensovibep in adults hospitalized with a COVID-19 diagnosis; first patient dose expected in Q2 2021
Ensovibep to be first non-antibody therapeutic assessed in ACTIV-3
Clinical trial includes an interim analysis after 300 patients
Separately, a global Phase 2-3 study in adults with mild to moderate symptoms is planned to be initiated in Q2 2021
Initial Phase 1 data support safety, tolerability and 2-3 week half-life of ensovibep
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced that ensovibep (formerly MP0420) is expected to be included in a global phase 3 randomized, controlled clinical trial as part of the National Institutes of Health
Molecular Partners AG: Molecular Partners and Novartis Announce Inclusion of COVID-19 Antiviral Candidate, ensovibep, in NIH-Sponsored ACTIV-3 Trial
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.